IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
This study has been completed.
Sponsor:
Robin, Alan L., M.D.
Information provided by:
Robin, Alan L., M.D.
ClinicalTrials.gov Identifier:
NCT00329095
First received: May 19, 2006
Last updated: May 22, 2006
Last verified: May 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
| Condition | Intervention | Phase |
|---|---|---|
| Glaucoma Ocular Hypertension | Drug: travoprost, latanoprost, or bimatoprost Drug: Additional ocular hypotensive medication | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures |
Resource links provided by NLM:
Further study details as provided by Robin, Alan L., M.D.:
Primary Outcome Measures:
- Compliance.
| Estimated Enrollment: | 60 |
| Study Start Date: | December 2005 |
| Estimated Study Completion Date: | April 2006 |
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Currently using one or two topical ocular hypotensive medications
Exclusion Criteria:
- Hypersensitivity to any component of medication
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095
Sponsors and Collaborators
Robin, Alan L., M.D.
Investigators
| Principal Investigator: | Alan L. Robin, MD | Alan L. Robin, M.D. |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00329095 History of Changes |
| Other Study ID Numbers: |
GMED-01 |
| Study First Received: | May 19, 2006 |
| Last Updated: | May 22, 2006 |
Keywords provided by Robin, Alan L., M.D.:
|
Glaucoma Compliance |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases Latanoprost |
Bimatoprost Travoprost Antihypertensive Agents |
ClinicalTrials.gov processed this record on July 27, 2017